AzTrials
AzTrials

Respiratory Syncytial Virus (RSV)Phase 1NCT02289820

A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

A Phase 1 study testing MEDI7510 and IIV in people with Respiratory Syncytial Virus (RSV), run by MedImmune LLC at 5 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. Read more about this study

Who is it for?
Ages 60 to 99 yearsHealthy volunteers can take part
Conditions the study is for
Respiratory Syncytial Virus (RSV)
What is being tested?
MEDI7510 and IIV
Could I receive a placebo?
No, everyone receives an active treatment
How many people
363 participants
Where
5 sitesUnited States
Study dates
5 Jan 2015to 24 Feb 2016
Phase
Phase 1
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 60 to 99 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age greater than or equal to 60 years
  • Ambulatory or ambulatory with assistance (not institutionalized, bedridden, or homebound)
  • Weight greater than 90 lbs
  • Hemoglobin greater than or equal to 10.5 g/dL for women and greater than or equal to 11 g/dL for men
  • Subject able to complete follow-up period of 360 days after dosing

Who cannot join

  • History of allergy to: any component of the vaccine; IIV or intolerance of IIV; eggs in adulthood
  • Receipt of seasonal flu shot within 60 days prior to dosing
  • Any unstable acute or chronic medical condition, including one that has resulted in change in therapy (medication or other) in the 30 days prior to randomization or hospitalization in the previous year or might be predicted to result in hospitalization in the year after enrollment. Subjects with severe, untreated or uncontrolled underlying medical disease that might either compromise subject safety or affect the ability to assess safety of the investigational product are excluded. Medications taken on an as-needed basis are permitted to start or stop during the 30 days prior to randomization unless they are medications not previously taken by the subject
  • Clinically significant abnormalities in screening laboratory assessments or screening ECG
  • History of hepatitis B or hepatitis C infection
  • History of Guillain-Barré syndrome
Show all 22Show fewer
  • Cognitive disorder such that informed consent cannot be obtained directly from the subject
  • Previous vaccination against RSV
  • History of or current autoimmune disorder
  • Immunosuppression caused by disease, including human immunodeficiency virus (HIV) infection, or medications. Any oral prednisone dosing within 30 days of enrollment or planned dosing within the 360-day follow-up period would disqualify. Expected need for immunosuppressive medications during the 360-day follow-up period would disqualify
  • History of splenectomy or of condition affecting splenic function (eg, hemoglobinopathy)
  • History of cancer within preceding 5 years other than treated non-melanoma skin cancer
  • Body Mass Index 40 or higher
  • Receipt of any nonstudy vaccine within 30 days prior to study dosing or expected receipt of nonstudy vaccine within 30 days after study dosing
  • Receipt of any investigational product in the 90 days prior to randomization or expected receipt of investigational product during the period of study follow-up
  • Receipt of immunoglobulins or blood products within 4 months of study dosing (120 days) or expected receipt of investigational product during the period of study follow-up
  • Current bleeding or clotting disorder including use of anticoagulants other than drugs with anti-platelet activity (such as nonsteroidal anti-inflammatory drugs, clopidogrel, ticagrelor or aspirin)
  • Expected receipt of antipyretic or analgesic medication on a daily or every other day basis from randomization through 72 hours after receipt of IP (Note: A daily dose of aspirin is not considered a contraindication to enrollment.)
  • Subjects who have significant scarring, tattoos, abrasions, cuts, or infections over the deltoid region of both arms that, in the investigators opinion, could interfere with evaluation of injection site local reactions
  • Concurrent enrollment in another clinical study that involves any invasive clinical procedure, including phlebotomy
  • History of alcohol or drug abuse or psychiatric disorder that, in the investigators opinion, would affect the subject's safety or compliance with study
  • Employees of individuals directly involved with the conduct of the study, individuals who themselves are involved with the conduct of the study, or immediate family members of such individuals

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

United States5 sites

  • Research Site

    Kansas City, Missouri

  • Research Site

    Nashville, Tennessee

  • Research Site

    Orlando, Florida

  • Research Site

    Raleigh, North Carolina

  • Research Site

    South Miami, Florida

Other trials in United States

About this study

Official title: A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults

The goal of this study is to evaluate the safety, tolerability and immunogenicity of ascending doses of adjuvant in combination with a single dosage level of RSV sF in adults 60 years or older who are healthy or who have stable, chronic underlying medical conditions. This study will also provide preliminary safety and immunogenicity data to support concurrent dosing of MEDI7510 with influenza vaccine (IIV), and to assess the safety of MEDI7510 at a dose previously assessed in the Phase 1a study.

Read the detailed description

A Phase 1b, double-blind, randomized, controlled cohort escalation study evaluating the safety, tolerability and immunogenicity of MEDI7510.

Approximately 264 subjects will be enrolled at approximately 5 study centers in the US and randomized by cohort (Cohort 1 [4:1]; Cohorts 2 and 3 [8:8:3]; Cohort 4 [5:1]) to receive a single intramuscular dose of 1 study vaccine (Cohorts 1 and 4) or a single intramuscular dose of each of 2 study vaccines (Cohorts 2 and 3) administered in contralateral arms.

Cohort 1: MEDI7510 formulation (n = 40) or IIV (n = 10) Cohort 2: MEDI7510 formulation and placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or placebo and IIV (n = 15) Cohort 3: MEDI7510 formulation and placebo (n = 40) or MEDI7510 formulation and IIV (n = 40) or placebo and IIV (n = 15) Cohort 4: MEDI7510 formulation (n = 20) or IIV (n = 4)

Being tested
MEDI7510, IIV
Keywords
RSV, Older adults, MEDI7510, Vaccine

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MEDI7510Biological

    RSV sF antigen plus adjuvant

  • IIVBiological

    Marketed Inactivated Influenza Vaccine

Study groups in NCT02289820
Study groupRoleWhat they receive
MEDI7510 (120 mcg sF + 1 mcg GLA), Cohort 1ExperimentalParticipants will receive a single dose of MEDI7510 (120 microgram [mcg] respiratory syncytial virus [RSV] soluble fusion protein [sF] plus 1.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by intramuscular (IM) injection on Day 1.
Receives: Biological: MEDI7510
MEDI7510 (120 mcg sF + 2.5 mcg GLA), Cohort 2ExperimentalParticipants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
Receives: Biological: MEDI7510; Biological: IIV
MEDI7510 (120 mcg sF + 5 mcg GLA), Cohort 3ExperimentalParticipants will receive a single dose of MEDI7510 (120 mcg RSV sF plus 5.0 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) plus IIV or MEDI7510 plus placebo administered by IM injection in contralateral arms on Day 1.
Receives: Biological: MEDI7510
MEDI7510 (80 mcg sF + 2.5 mcg GLA), Cohort 4ExperimentalParticipants will receive a single dose of MEDI7510 (80 mcg RSV sF plus 2.5 mcg glucopyranosyl lipid A in 2% volume per volume stable emulsion) administered by IM injection on Day 1.
Receives: Biological: MEDI7510
Inactivated Influenza Vaccine (IIV)Active comparatorParticipants will receive a single dose of IIV by intramuscular injection in contralateral arms on Day 1.
Receives: Biological: IIV

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Solicited Symptoms

    Solicited symptoms are events that are considered likely to occur post dosing and included the local reaction (pain, tenderness or soreness, redness, and swelling at the site of injection) to investigational product (IP) injection and systemic symptoms (fever greater than or equal to [>=] 100.4°F [>=38°C] by any route, headache, generalized muscle aches, and fatigue or tiredness) that might be related to IP injection. Solicited symptoms were not coded using Medical Dictionary for Regulatory Activities (MedDRA) and summarized regardless of whether or not they are treatment emergent. The percentage of participants with solicited symptoms were recorded during Days 1 (day of dosing) through 7.

    Measured: Day 1 to Day 7

  2. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Treatment-emergent were the events between administration of study drug and including the follow-up period through Day 29. The AEs were summarized using the Medical Dictionary for Regulatory Activities version 18.1.

    Measured: From Day 1 to Day 29

  3. Percentage of Participants With Treatment-emergent Serious Adverse Events

    A serious adverse event (SAE) was an AE resulting in any of following reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk), persistent or significant disability/incapacity, congenital anomaly, and a medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.

    Measured: From Day 1 to Day 361

  4. Percentage of Participants With New Onset Chronic Diseases (NOCDs)

    A NOCD was a newly diagnosed medical condition that is of a chronic, ongoing nature. It was observed after receiving study drug and was assessed by investigator as medically significant. All NOCDs were recorded from the time of dosing through the day of the last participant contact (Day 361 visit).

    Measured: From Day 1 to Day 361

  5. Percentage of Participants With Treatment-emergent Adverse Events of Special Interest (TEAESI)

    An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor. Treatment emergent AESIs were collected from the time of dosing through the day of the last participant contact (Day 361 visit).

    Measured: From Day 1 to Day 361

Secondary outcomes (10)

  1. Geometric Mean Titers (GMTs) of Serum Antibodies Against Respiratory Syncytial Virus (RSV) by RSV A Microneutralization Assay

    GMTs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay at Baseline and the results through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A. Immunogenicity population is defined as all participants in ATP who had no protocol deviation judged to have the potential to interfere with generation or interpretation of an immune response.

    Measured: Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361

  2. Geometric Mean Fold Rises (GMFRs) of Serum Antibodies Against RSV by RSV A Microneutralization Assay

    GMFRs of serum antibodies against RSV, as assessed by the RSV A microneutralization assay from Baseline line through Day 361 were presented. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.

    Measured: Day 29, 61, 91, 181, 271, and 361

  3. Percentage of Participants With Post-dose Seroresponse to RSV by RSV A Microneutralization Assay

    Seroresponse defined as a greater than or equal to (>=) 3-fold rise in titer from baseline. Humoral immunogenicity samples was used to assess RSV A neutralizing antibody. Humoral immunity against RSV was assessed by a microneutralization assay for RSV A.

    Measured: Day 29

  4. Geometric Mean Concentrations of Serum Antibodies Against RSV by Anti F Immunoglobulin G (IgG) Assay

    Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.

    Measured: Baseline (Day 1), Day 29, 61, 91, 181, 271, and 361

  5. GMFRs of Serum Antibodies Against RSV by Anti F IgG Assay

    The Anti F IgG antibodies were derived from the RSV-specific 4-plex MSD assay developed on the Meso Scale discovery platform. Humoral immunogenicity samples were used to assess anti-F IgG antibodies measured using a 4-plex Meso Scale Discovery (MSD) platform assay. Results through Day 361 are presented.

    Measured: Day 29, 61, 91, 181, 271, and 361

  6. Percentage of Participants With Post-dose Seroresponse to RSV by Anti-F IgG Assay

    Seroresponse defined as a greater than or equal to (>=) 3-fold rise from baseline. Humoral immunity against RSV was assessed by an Anti-F IgG assay derived from the RSV-specific 4-plex MSD assay.

    Measured: Day 29

  7. Ratios of GMTs and GMFRs of Hemagglutination Inhibition (HAI) Antibodies

    The ratio of post-dose HAI antibody GMTs and GMFRs in the IIV group and the MEDI7510 plus IIV group was provided by strain and by cohort for Cohorts 2 and 3 to check the effect of MEDI7510 on IIV when administered together. Humoral immunity against influenza consisting of HAI antibody to strains antigenically matched to those contained in the IIV was assessed on Day 29 by each strain (H1N1, H3N2, B/Yamagata).

    Measured: Day 29

  8. Geometric Mean Counts of Cellular Immune Response Against RSV by Respiratory Syncytial Virus Fusion Protein (RSV F) Interferon Gamma (IFNγ) Enzyme-linked Immunosorbent Spot (ELISPOT) Assay

    The Geometric Mean Counts assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.

    Measured: Baseline (Day 1) and Day 8

  9. GMFRs of Cellular Immune Response Against RSV by RSV F IFNγ ELISPOT Assay

    The GMFRs assessed by the ELISPOT assay for F protein-specific gamma interferon-producing T cells was performed using RSV F peptides. Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples

    Measured: Day 8

  10. Percentage of Participants With Post-dose Cell-mediated Immune Response to RSV F by RSV F Peptide Pool IFNγ ELISPOT

    Seroresponse defined as a greater than or equal to (>=) 3-fold rise from baseline. The Cell-mediated immunity was assessed using an IFNγ ELISPOT assay to measure the T-cell responses to the RSV F peptide pool using thawed, cryopreserved peripheral blood mononuclear cell samples.

    Measured: Day 8

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2014 (estimated)
  2. Study start5 Jan 2015
  3. Primary completion24 Feb 2016
  4. Study completion24 Feb 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
363 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02289820
Sponsor's protocol ID
D4420C00004
Status last verified
Feb 2018
First submitted
10 Nov 2014
Last updated
15 Mar 2018
Data monitoring committee
Yes

Publications

  • Chang LA, Phung E, Crank MC, Morabito KM, Villafana T, Dubovsky F, Falloon J, Esser MT, Lin BC, Chen GL, Graham BS, Ruckwardt TJ. A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine. Sci Transl Med. 2022 Dec 21;14(676):eade0424. doi: 10.1126/scitranslmed.ade0424. Epub 2022 Dec 21.

    PubMed 36542692

  • Falloon J, Talbot HK, Curtis C, Ervin J, Krieger D, Dubovsky F, Takas T, Yu J, Yu L, Lambert SL, Villafana T, Esser MT. Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses. Clin Vaccine Immunol. 2017 Sep 5;24(9):e00157-17. doi: 10.1128/CVI.00157-17. Print 2017 Sep.

    PubMed 28679495

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing MEDI7510 and IIV in people with Respiratory Syncytial Virus (RSV), run by MedImmune LLC at 5 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Feb 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Solicited Symptoms (time frame: Day 1 to Day 7). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02289820, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Mar 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in